PolyMASC Pharmaceuticals PLC (now merged with Urigen Pharmaceuticals Inc)
PolyMASC’s patented pegylation and liposomes technologies helped them to be the first university spin out company to float on the London Alternative Investment Market in 1995. The company merged with Valentis Inc. in 2000. In July 2007, Urigen Pharmaceuticals Inc completed a reverse merger with Valentis Inc, Urigen Pharmaceuticals is a speciality pharmaceutical company dedicated to the development and commercialisation of therapeutic products for urological disorders.